In 2026, the landscape of key opinion leaders (KOLs) in hematology-oncology is undergoing a dramatic shift due to the rise and rapid adoption of bispecific antibodies. These innovative biologics have not only changed clinical practice but also redefined who the influential voices are within the field. Unlike previous eras dominated by CAR-T trials, this new wave includes KOLs who have made their mark through groundbreaking work with drugs like mosunetuzumab, epcoritamab, glofitamab, talquetamab, and teclistamab.
The publication velocity in the bispecific arena is unprecedented. Researchers are not only publishing at an accelerated rate but also engaging more proactively on social media platforms to disseminate their findings quickly. This real-time sharing of data and insights has become a critical component for staying ahead in this rapidly evolving field.
Teams that have identified these rising stars early on are seeing significant benefits. Early engagement with these KOLs can lead to exclusive access to emerging data, fostering deeper relationships built on mutual trust and respect. Companies that fail to recognize the value of these new voices risk falling behind as more pharmaceutical players pivot their strategies towards bispecifics.
The shift is not just about identifying promising individuals; it's also about understanding how these KOLs are shaping the conversation around clinical utility, efficacy, and safety. For example, mosunetuzumab’s unique mechanism of action targeting both CD20 on B cells and CD3 on T cells has opened new avenues for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Epcoritamab's dual-targeting approach against BCMA and CD3 is changing the landscape in multiple myeloma, offering a non-hematopoietic stem cell transplant option.
Pharma Medical Affairs teams need to adapt their strategies by integrating these newer KOLs into key decision-making processes. Commercial teams must also recognize that success in this new era will come from understanding not just the clinical data but also the narrative around it, as told by these emerging leaders. Engaging with them early and effectively can provide a competitive edge, ensuring that companies are at the forefront of innovation rather than merely following trends.
The KOL landscape is evolving faster than ever before. For those in hematology-oncology looking to stay ahead, embracing this shift towards bispecifics and understanding their impact on clinical practice is non-negotiable. The teams that can navigate this new terrain successfully will undoubtedly reap the rewards of early engagement with these innovative leaders.